Brief: UCB's Rystiggo Receives Approval In Japan For Two New Administration Methods
May 9 (Reuters) - Ucb SA UCB.BR: RYSTIGGO (ROZANOLIXIZUMAB) RECEIVES APPROVAL IN JAPAN FOR TWO NEW ADMINISTRATION METHODS AS UCB BEGINS ONWARD PROGRAM FOR PATIENT SUPPORT COMPLEMENTING THIS APPROVAL, UCB JAPAN WILL LAUNCH A HOME DELIVERY SERVICE FOR RYSTIGGO Source text: here Further company coverage: UCB.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside